Radiothérapie vectorisée : les nouvelles molécules

Although the efficacy of radionuclide therapy has been demonstrated in several indications, the development of this new therapeutic modality is limited. However, promising results have been obtained, especially using different radiolabeled somatotatin analogs for neuroendocrine tumors or radioimmunotherapy for lymphoma. Toxicity is limited, particularly if patients are selected based on their background. The use of new vectors (bombesin, anti-PMSA monoclonal antibody), pretargeting system and innovative radionuclides (Copper-67, Astatine-211) suggests interesting perspectives, particularly to target small tumor masses or residual disease.